Hua Jing, Gross Nikolai, Schulze Brita, Michaelis Uwe, Bohnenkamp Hermann, Guenzi Eric, Hansen Lutz L, Martin Gottfried, Agostini Hansjürgen T
University Eye Hospital, Albert-Ludwigs University of Freiburg, Killianstrasse 5, Freiburg im Breisgau, Germany
Mol Vis. 2012;18:1045-54. Epub 2012 Apr 26.
Precise monitoring of active angiogenesis in neovascular eye diseases such as age-related macular degeneration (AMD) enables sensitive use of antiangiogenic drugs and reduces adverse side effects. So far, no in vivo imaging methods are available to specifically label active angiogenesis. Here, we report such a technique using fluorophore-labeled cationic liposomes (CL) detected with a standard clinical in vivo scanning laser ophthalmoscope (SLO).
C57Bl/6 mice underwent laser coagulations at day 0 (d0) to induce choroidal neovascularization (CNV). Liposomes labeled with Oregon green, rhodamine (Rh), or indocyanine green (ICG) were injected into the tail vein at various time points after laser coagulation, and their fluorescence was observed in vivo 60 min later using an SLO, or afterwards in choroidal flatmounts or cryosections.
SLO detected accumulated fluorescence only in active CNV lesions with insignificant background noise. The best signal was obtained with CL-ICG. Choroidal flatmounts and cryosections of the eye confirmed the location of retained CL in CNV lesions. Neutral liposomes, in contrast, showed no accumulation.
These results establish fluorophore-labeled CL as high affinity markers to selectively stain active CNV. This novel, non-invasive SLO imaging technique could improve risk assessment and indication for current intraocular antiangiogenic drugs in neovascular eye diseases, as well as monitor therapeutic outcomes. Labeling of angiogenic vessels using CL can be of interest not only for functional imaging in ophthalmology but also for other conditions where localization of active angiogenesis is desirable.
精确监测诸如年龄相关性黄斑变性(AMD)等新生血管性眼病中的活跃血管生成,有助于敏感地使用抗血管生成药物并减少不良副作用。到目前为止,尚无用于特异性标记活跃血管生成的体内成像方法。在此,我们报告一种使用荧光团标记的阳离子脂质体(CL)的技术,该技术可通过标准临床体内扫描激光检眼镜(SLO)进行检测。
C57Bl/6小鼠在第0天(d0)接受激光凝固以诱导脉络膜新生血管形成(CNV)。在激光凝固后的不同时间点将用俄勒冈绿、罗丹明(Rh)或吲哚菁绿(ICG)标记的脂质体注入尾静脉,并在60分钟后使用SLO进行体内荧光观察,或之后在脉络膜平铺标本或冷冻切片中观察。
SLO仅在活跃的CNV病变中检测到累积荧光,背景噪声不明显。使用CL-ICG获得的信号最佳。眼睛的脉络膜平铺标本和冷冻切片证实了CL在CNV病变中的保留位置。相比之下,中性脂质体没有显示出积累。
这些结果确立了荧光团标记的CL作为选择性染色活跃CNV的高亲和力标记物。这种新颖的非侵入性SLO成像技术可以改善新生血管性眼病中当前眼内抗血管生成药物的风险评估和适应证,以及监测治疗效果。使用CL标记血管生成血管不仅对眼科功能成像有意义,而且对其他需要定位活跃血管生成的情况也有意义。